Last reviewed · How we verify
QLS1128
QLS1128 is a small molecule inhibitor targeting a specific molecular pathway in phase 3 development by Qilu Pharmaceutical.
At a glance
| Generic name | QLS1128 |
|---|---|
| Sponsor | Qilu Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Limited public information is available on QLS1128's precise mechanism of action. As a phase 3 candidate from Qilu Pharmaceutical, it represents an investigational compound under active clinical evaluation, but detailed mechanistic data have not been widely disclosed in accessible literature.
Approved indications
Common side effects
Key clinical trials
- A Study to Compare QLS1128 With Placebo in Symptomatic Participants With Mild to Moderate COVID-19 (PHASE3)
- A Phase 2 Study to Evaluate the Efficacy and Safety of QLS1128 Orally in Symptomatic Participants With Mild to Moderate COVID-19 (PHASE2)
- A Study of QLS1128 and in Combination With Ritonavir in Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |